We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Early Stage Melanoma Identified by Simple Blood Test

By LabMedica International staff writers
Posted on 20 Sep 2017
Print article
Image: A human malignant melanoma cell viewed through a fluorescent, laser-scanning confocal microscope. Invasive structures involved in metastasis appear as greenish-yellow dots, while actin (green) and vinculin (red) are components of the cell’s cytoskeleton (Photo courtesy of Vira V. Artym, PhD, PMP).
Image: A human malignant melanoma cell viewed through a fluorescent, laser-scanning confocal microscope. Invasive structures involved in metastasis appear as greenish-yellow dots, while actin (green) and vinculin (red) are components of the cell’s cytoskeleton (Photo courtesy of Vira V. Artym, PhD, PMP).
Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin but may rarely occur in the mouth, intestines, or eye.

Melanoma is an aggressive cancer and once it has spread through the body, average survival is six to nine months, with less than 40% of patients surviving five years. New Zealand and Australia have the highest incidence of melanoma in the world. More than 2,400 New Zealanders a year are diagnosed with melanoma and around 350 New Zealanders die from it every year.

Scientists at the Edith Cowan University (ECU, Perth, Australia) have developed blood-based biomarkers for early diagnosis, prognosis and personalization of treatment in melanoma. Through the implementation of cutting-edge technologies and next generation sequencing the team scrutinized novel biomarkers such as Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA). In addition, they expanded the study of miRNA, exosomes and autoantibodies for improved specificity and sensitivity. The technologies are now being expanded to include prostate, breast and lung cancers. The team is also monitoring the DNA of patients who finish treatment to see if they remain disease-free.

Mel Ziman, PhD, associate dean and head of the ECU Melanoma Research Group, said, “At the moment, suspicious lesions are biopsied and examined by a pathologist. In some cases diagnosis is difficult and not always certain, particularly with very early melanomas and those without color. We’ve identified several auto antibodies that are produced by the body in response to melanoma and have developed a one-step blood test that will search for any one of these identifiers, which provides rapid, diagnostic certainty.” The study was presented a meeting titled “Melanoma research and therapy in New Zealand: raising the bar through collaborative action” held on September 9, 2017, in Queenstown, New Zealand and organized by Melanoma New Zealand.

Related Links:
Edith Cowan University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.